Overall survival gain with lenvatinib vs. placebo in radioactive iodine refractory differentiated thyroid cancer (RR-DTC): An updated analysis

Date 26 September 2015
Event European Cancer Congress 2015
Session Head and Neck Cancer
Topics Head and Neck Cancers
Presenter Wirth, L.